Phase II study of ONYX-015 in patients with hepatobiliary tumors with p53 correlative studies

被引：0
|
作者：
Wadler, S
Makower, D
Yu, B
Tan, JY
Rozenblit, A
Kaufman, H
Edelman, M
Lane, M
Zwiebel, J
Horwitz, M
机构：
[1] Cornell Univ, Weill Med Coll, Div Hematol Oncol, New York, NY USA
[2] Albert Einstein Coll Med, Dept Oncol, Bronx, NY 10467 USA
[3] Cornell Univ, Weill Med Coll, Dept Pathol, New York, NY USA
[4] Albert Einstein Coll Med, Dept Radiol, Bronx, NY 10467 USA
[5] Albert Einstein Coll Med, Dept Surg, Bronx, NY 10467 USA
[6] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA
[7] Albert Einstein Coll Med, Dept Microbiol Immunol, Bronx, NY 10467 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2002年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
468
引用
收藏
页码：S140 / S141
页数：2
相关论文
共 50 条
  • [21] A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients
    J Nemunaitis
    N Senzer
    S Sarmiento
    Y-A Zhang
    R Arzaga
    B Sands
    P Maples
    A W Tong
    Cancer Gene Therapy, 2007, 14 : 885 - 893
  • [22] A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients
    Nemunaitis, J.
    Senzer, N.
    Sarmiento, S.
    Zhang, Y-A
    Arzaga, R.
    Sands, B.
    Maples, P.
    Tong, A. W.
    CANCER GENE THERAPY, 2007, 14 (11) : 885 - 893
  • [23] A phase II trial of an attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant dysplastic oral lesions
    Cohen, EEW
    Papadimitrakopoulou, VA
    Silverman, SJ
    Recant, W
    El-Naggar, A
    Hong, WK
    Freeman, S
    Vokes, EE
    Rudin, CM
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S84 - S84
  • [24] Phase I dose escalation trial of intravenous infusion of ONYX-015 in patients with refractory cancer
    Nemunaitis, J
    Cunningham, C
    Edelman, G
    Berman, B
    Kirn, D
    CANCER GENE THERAPY, 1999, 6 (06) : S16 - S17
  • [25] Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer
    Nemunaitis, J
    Khuri, F
    Ganly, I
    Arseneau, J
    Posner, M
    Vokes, E
    Kuhn, J
    McCarty, T
    Landers, S
    Blackburn, A
    Romel, L
    Randlev, B
    Kaye, S
    Kirn, D
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) : 289 - 298
  • [26] Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015):: results of Phase I and II trials
    Kirn, D
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2001, 1 (03) : 525 - 538
  • [27] Selectively replicating oncolytic adenoviruses for the treatment of cancer: clinical development of ONYX-015 (p53-targeted) and preclinical studies with ONYX-838 (RB pathway-targeted).
    Kim, D
    Nemunaitis, J
    Heise, C
    Hermiston, T
    CANCER GENE THERAPY, 1999, 6 (04) : 389 - 389
  • [28] A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma
    Hecht, JR
    Bedford, R
    Abbruzzese, JL
    Lahoti, S
    Reid, TR
    Soetikno, RM
    Kirn, DH
    Freeman, SM
    CLINICAL CANCER RESEARCH, 2003, 9 (02) : 555 - 561
  • [29] Selectively-replicating oncolytic adenoviruses for the treatment of cancer: Clinical development of ONYX-015 (p53-targeted) and preclinical studies with ONYX-838 (RB pathway-targeted)
    Kirn, D
    Nemunaitis, J
    Heise, C
    Hermiston, T
    CANCER GENE THERAPY, 1999, 6 (06) : S10 - S10
  • [30] Selectively-replicating oncolytic adenoviruses for the treatment of cancer: Clinical development of ONYX-015 (p53-targeted) and preclinical studies with ONYX-838 (RB pathway-targeted).
    Kirn, D
    Nemunaitis, J
    Heise, C
    Hermiston, T
    GENE THERAPY, 1999, 6 : S5 - S5
12345